3 New Strong Buy Ratings from Top-Rated Analysts: 10/23/2025
The recent precious metal stock dip could create excellent opportunities. Here’s the latest from our Strong Buy Stocks from Top Wall Street Analysts screener:
- Hudbay Minerals (HBM) is at the top of its industry
- Aura Minerals (AUGO) has a triple-thread of strong fundamentals that point to sustained growth
- Analysts are circling Biocryst Pharmaceuticals (BCRX) on bullish acquisition news
P.S. Want more great stocks chosen for you? Check out Zen Investor.
A note from our sponsors...
Sell Nvidia and replace it with WHAT?! The AI trade is running full throttle. But it won't last forever. It's not time to abandon AI stocks completely, but it IS time to prepare for the inevitable slowdown. Futurist Eric is giving away 7 free trade ideas in his "Sell This, Buy That" research package, where he reveals which market moves you need to make today (starting with getting rid of Nvidia stock.) Access these trade ideas here.1. Hudbay Minerals (HBM)
This diversified miner of copper, gold, and zinc currently has several expansion projects targeting continued growth. The company is benefiting from surging copper prices, electrification demand, and disciplined cost controls.
Zen Rating: B (Buy) — see full analysis >
Recent Price: $14.79 — get current quote >
Max 1-year forecast: $19.50
Why we're watching:
- Analyst support: While only one of the analysts we track issues a rating on HBM, it’s a Strong Buy, suggesting 28% potential upside in the coming year. See ratings for HBM
- Bullish commentary: Recent writeups on outlets like Seeking Alpha highlights top momentum, market-beating returns (+62% YoY), and strong cash flows as HBM benefits from rare earth/minerals up-cycles and new project rollouts.
- Industry context: HBM is presently the #1 highest-rated stock in the Copper industry (Industry Rating: B, 6 total companies).
- High Zen Rating: With a Zen Rating of B (Buy), HBM is in a class of stocks that have historically delivered 19.88% annual gains.
- Digging into the Component Grades, HBM looks solid, with Bs for Growth, Financials, and Momentum. (See all 7 Zen Component Grades here >)
2. Aura Minerals (AUGO)
Aura Minerals is a growing gold and copper producer operating across the Americas, with operations benefitting from record commodity forecasts and bullish sector upgrades. Renewed analyst enthusiasm comes as gold and silver price targets were revised sharply upwards for 2026.
Zen Rating: B (Buy) — see full analysis >
Recent Price: $36.71 — get current quote >
Max 1-year forecast: $46.60
Why we're watching:
- Analyst support: AUGO only has 2 ratings among the analysts we track, but they are both Strong Buys, with both analysts suggesting 30% or higher potential upside in the coming year. See the ratings
- For example, Bank of America researcher Lawson Winder (top 24%) hiked his price target, noting a 16% average boost across the group as BoA’s commodities team now expects $5,000 gold, fueling upside across key producers.
- Industry ranking context: AUGO is the 10th-ranked stock of 51 in Gold (Industry Rating: B).
- Zen Rating highlights: In addition to an overall Zen Rating of B, AUGO enjoys strong Component Grades for Growth and Momentum (both A ratings) and Financials (B rating), suggesting a strong foundation for sustained growth. See all 7 Zen Component Grades here >
3. Biocryst Pharmaceuticals (NASDAQ: BCRX)
This late-stage biotech targets rare diseases. Right now, the company is gaining analyst support on a proposed $700M acquisition, which could potentially derisk the pipeline and position BCRX for substantial revenue growth.
Zen Rating: A (Strong Buy) — see full analysis >
Recent Price: $6.63 — get current quote >
Max 1-year forecast: $30.00
Why we're watching:
- Analyst support: 4 Strong Buy, 5 Buy, 1 Hold (10 total). See the ratings
TD Cowen researcher Stacy Ku (bottom 17%) reinstated coverage with a Buy rating, citing the Astraia Therapeutics deal as a pipeline derisking catalyst; navenibart’s Phase 3 profile is attracting enthusiasm from key opinion leaders.
Additional commentary: The Street projects BCRX’s 2026 EPS to return to positive territory, with consensus creating a striking forecast for 200%+ upside over the next year, backed by high analyst conviction.
- Industry ranking context: BCRX is a top-rated Biotech name with triple-digit price target upside potential.
- Component Grades: See detailed breakdown >
What to Do Next?
Want to get in touch? Email us at news@wallstreetzen.com.
Keep Reading
See All News
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.